In 2000, in response to one of the greatest scourges of our time in a country disproportionately affected by this disease, the Government of Botswana, The Merck Company Foundation/Merck & Co., Inc., and the Bill & Melinda Gates Foundation established the African Comprehensive HIV/AIDS Partnerships (ACHAP) to support and enhance Botswana’s response to the HIV and AIDS epidemic through a comprehensive approach to HIV and AIDS prevention, treatment, care and support and impact mitigation. Since 2001, The Merck Company Foundation and the Gates Foundation have committed $106.5 million to the partnership. In addition, Merck agreed to donate its antiretroviral (ARV) medicines — STOCRIN and CRIXIVAN — to Botswana’s national antiretroviral (ARV) treatment program — known as Masa (or “new dawn”) — for the partnership’s duration. In November 2008, Merck expanded its donation to include ATRIPLA and ISENTRESS.

The content on this page was last modified on September 15, 2009.

Merck & Co., Inc., Whitehouse Station, NJ, USA, and Schering-Plough Corporation, Kenilworth, NJ, USA, are now one company. We have combined our global operations under the name Merck & Co., Inc. We are working to update our corporate responsibility Web site to reflect our new, combined, global organization.